Skip to Main Content (Press Enter)

Logo UNIBS
  • ×
  • Home
  • People
  • Organizations
  • Expertise & Skills
  • Outputs
  • Jobs
  • Degrees
  • Courses
  • Third Mission
  • Equipment

Expertise & Skills
Logo UNIBS

|

Expertise & Skills

unibs.it
  • ×
  • Home
  • People
  • Organizations
  • Expertise & Skills
  • Outputs
  • Jobs
  • Degrees
  • Courses
  • Third Mission
  • Equipment
  1. Outputs

Single‐cell‐based non‐invasive screening for fetal pathogenic microimbalances using maternal blood: comparison with invasive prenatal diagnosis

Academic Article
Publication Date:
2026
Abstract:
Objective: Pathogenic or likely pathogenic copy-number variants (p/lpCNVs) are a significant cause of perinatal morbidity and mortality. Current prenatal screening based on cell-free DNA (cfDNA) fails to detect the majority of microimbalances (microdeletions/microduplications), leaving a significant residual risk of undetected chromosomal abnormalities. This study evaluated the clinical performance of a novel single-cell-sequencing-based non-invasive prenatal testing (scsbNIPT) method utilizing circulating extravillous trophoblasts (cEVTs) for the detection of fetal p/lpCNVs, particularly microimbalances < 8 Mb. Methods: This was a prospective, blinded, observational multicenter cohort study of 1390 high-risk pregnant women undergoing prenatal invasive diagnostic testing between November 2021 and December 2023. A 20-mL maternal blood sample was collected from each subject between 11 + 0 and 22 + 6 weeks' gestation prior to invasive sampling. cEVTs were isolated and subjected to whole-genome sequencing, using a proprietary workflow. scsbNIPT results were compared with standard invasive prenatal diagnostic results obtained by karyotyping and/or chromosomal microarray analysis. Results: scsbNIPT showed a sensitivity of 92.9% (95% CI, 76.5–99.1%) and a specificity of 98.2% (95% CI, 97.0–99.0%) for the detection of genome-wide microimbalances measuring ≥ 300 kb to < 8 Mb. The sensitivity for p/lpCNVs ≥ 300 kb in pregnancies screened at 11 + 0 to 14 + 6 weeks was 100% (95% CI, 83.9–100%). For trisomy 21, the sensitivity of scsbNIPT was 98.0% (95% CI, 92.9–99.8%) and the specificity was 99.7% (95% CI, 99.0–99.9%). Conclusions: This study demonstrates the scientific validity and clinical utility of scsbNIPT for the non-invasive detection of genome-wide fetal p/lpCNVs, particularly microimbalances, with high sensitivity and a resolution comparable to that of chromosomal microarray analysis. scsbNIPT may offer more complete screening for genome-wide p/lpCNVs, markedly lowering the residual risk early in pregnancy compared with existing cfDNA-based methods. © 2026 Menarini Silicon Biosystems. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
CRIS type:
1.1 Articolo in rivista
Keywords:
circulating extravillous trophoblast; clinical utility; clinically relevant CNV; DNA-based first-trimester screening; fetal microimbalance; genome-wide screening; intentional screening; residual risk; single-cell NIPT; single-cell sequencing
List of contributors:
Stampalija, T.; Forcato, C.; Grati, F. R.; Volpe, P.; De Robertis, V.; Izzi, C.; Bertucci, E.; Fabietti, I.; Novelli, A.; Ornaghi, S.; Pasquini, L.; Bevilacqua, E.; Paladini, D.; Ghi, T.; Lattuada, D.; Dori, M.; Mercatelli, D.; Dal Molin, A.; Buson, G.; Bolognesi, C.; Doffini, A.; Musci, T. J.; Ferrazzi, E.; Null, Null
Authors of the University:
IZZI CLAUDIA
Handle:
https://iris.unibs.it/handle/11379/656566
Full Text:
https://iris.unibs.it/retrieve/handle/11379/656566/404647/Singlecellbased%20noninvasive%20screening%20UOG%202026.pdf
Published in:
ULTRASOUND IN OBSTETRICS & GYNECOLOGY
Journal
  • Support
  • Privacy
  • Use of cookies
  • Legal notes

Powered by VIVO | Designed by Cineca | 26.11.1.0